Saarbrücken, Germany – New insights into the pathogenesis of Alzheimer’s disease could unlock novel therapeutic approaches and help to prevent the disease. A study led by Professors Marcus Grimm and Tobias Hartmann at the Rhineland Campus of the SRH University of Applied Health Sciences in Leverkusen and at Saarland University...
Latest News
Charlottesville, VA – University of Virginia Alzheimer’s researchers have discovered how harmful tau proteins damage the essential operating instructions for our brain cells, a finding which could lead to new treatments. The toxic protein, the researchers found, warps the shape of the nuclei of nerve cells, or neurons. This alters...
London, England – Five cases of Alzheimer’s disease are believed to have arisen as a result of medical treatments decades earlier, reports a team of UCL and UCLH researchers. Alzheimer’s disease is caused by the amyloid-beta protein, and is usually a sporadic condition of late adult life, or more rarely...
FRAMINGHAM, Mass. — Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for...
LILLE, France — ALZPROTECT is thrilled to announce that it has received favorable feedback from both the U.S. food and drug administration (FDA) and European Medicines Agency (EMA) regarding the regulatory path for advancing the clinical development of Ezeprogind/AZP2006 for patients with PSP. This significant milestone follows the already very...
DUBLIN — Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic autoimmune disease characterized by muscle weakness which can be life-threatening. Thomas Lynch, Chairman and Chief Executive Officer of Amarin,...
ALISO VIEJO, Calif. and MENLO PARK, Calif. — Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies’ selection by the University of California, Irvine (UCI)...
Philadelphia, PA – A study of more than 250 persons undergoing surgical therapy for Cushing’s disease (CD) or nonfunctioning pituitary adenomas (NFPAs) found that patients who achieved remission of CD were more likely than those with surgically treated NFPAs to develop new-onset autoimmune disease within 3 years after remission. The...
DALLAS, TX — Adults who reported drinking two liters (about 67 ounces) or more of sugar- or artificially sweetened drinks per week had a higher risk of an irregular heart rhythm known as atrial fibrillation compared with adults who drank fewer such beverages, according to new research published today in Circulation: Arrhythmia...
THOUSAND OAKS, Calif. — Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice...